RxDoctor Payments Data

Todd Williamson, DO

Ophthalmology · Hattiesburg, MSNPI 1881702447

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 56.7% of the total.

$2,967in general payments, 2019–2025

Across 149 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$233
  • Ocular Therapeutix, Inc.$220
  • Aerie Pharmaceuticals, Inc.$199
  • Johnson & Johnson Surgical Vision, Inc.$142
  • Novartis$100
  • plus $390 from 9 others

What the payments were for

  • Food & beverage$2,967100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,967 in reported general payments places this provider in the 60th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$688,633
Medicare patients
1,943
Services billed
6,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost132$43,202
RestasisCyclosporine41$37,970
Prednisolone Acetate658$19,755
Ketorolac Tromethamine597$10,512
Cyclosporine16$9,366
Ofloxacin584$6,934
Latanoprost715$5,107
Tobramycin-DexamethasoneTobramycin/Dexamethasone133$4,725
Alphagan PBrimonidine Tartrate14$4,677
Brimonidine Tartrate188$2,937
Travoprost25$2,692
Timolol Maleate274$2,402
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat96$1,366
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$1,281
Fluorometholone21$1,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$1,683$85,849187 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →